• Could an old Amgen-developed RA drug make CAR-T treatments safer? fiercebiotech
    June 11, 2018
    The personalized CAR-T cells that are FDA-approved to treat blood cancers, Gilead’s Yescarta and Novartis’s Kymriah, can raise the risk of a side effect that has been challenging to prevent and treat: cytokine release syndrome (CRS).
PharmaSources Customer Service